Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2b study of epcoritamab combinations in non-Hodgkin lymphoma
MOH_2022-05-02_010732Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability. Started Apr 2022; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2022-05-02_010732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-02_010732.